Q2 2024 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2024-08-14 · accession 0001814554-24-000010
$428.0M
Reported value
13
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $124.3M | 29.0% | 10,360,945 | Common | SOLE |
| 016259202 | — | ALIMERA SCIENCES INC | $93.6M | 21.9% | 16,835,154 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $36.4M | 8.50% | 1,435,993 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $34.3M | 8.01% | 1,525,730 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $28.4M | 6.64% | 4,598,737 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $26.7M | 6.23% | 1,843,756 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $23.5M | 5.50% | 2,167,790 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $22.2M | 5.19% | 514,711 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $13.5M | 3.16% | 1,042,889 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $8.7M | 2.04% | 745,758 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $7.0M | 1.64% | 582,078 | Common | SOLE |
| 44975P103 | NBP | I MAB | $5.6M | 1.32% | 3,374,791 | Common | SOLE |
| 69012T305 | OTLK | OUTLOOK THERAPEUTICS INC | $3.7M | 0.86% | 500,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.